Novel Heterocyclic Compounds as Bromodomain Inhibitors
申请人:Liu Shuang
公开号:US20140179648A1
公开(公告)日:2014-06-26
The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
本公开涉及一些化合物,这些化合物通过结合溴结构域对BET蛋白功能进行抑制,并且它们在治疗中的应用。
NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS
申请人:Zenith Epigenetics Ltd.
公开号:US20170143731A1
公开(公告)日:2017-05-25
The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy.
US9271978B2
申请人:——
公开号:US9271978B2
公开(公告)日:2016-03-01
US9598367B2
申请人:——
公开号:US9598367B2
公开(公告)日:2017-03-21
[EN] IL-17A MODULATORS<br/>[FR] MODULATEURS DE IL-17A
申请人:SANOFI SA
公开号:WO2021239745A1
公开(公告)日:2021-12-02
The present invention relates to compounds that are IL-17A modulators. The compounds have the structural Formula I defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of diseases or disorders associated with modulation of IL-17A activity.